Investigational Drug Information for chiauranib
What is the drug development status for chiauranib?
chiauranib is an investigational drug.
There have been 17 clinical trials for chiauranib.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 13th 2024.
The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Akeso, and Shenzhen Chipscreen Biosciences Co.Ltd.
There are seventy-five US patents protecting this investigational drug and twenty-seven international patents.
Summary for chiauranib
| US Patents | 75 |
| International Patents | 27 |
| US Patent Applications | 174 |
| WIPO Patent Applications | 105 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 2 (2024-08-13) |
| Vendors | 37 |
Recent Clinical Trials for chiauranib
| Title | Sponsor | Phase |
|---|---|---|
| Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | Chipscreen Biosciences, Ltd. | PHASE2 |
| Anti-PD-1 and CTLA-4 Bispecific Antibody AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | Chipscreen Biosciences, Ltd. | Phase 1/Phase 2 |
| Anti-PD-1 and CTLA-4 Bispecific Antibody AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | Akeso | Phase 1/Phase 2 |
Clinical Trial Summary for chiauranib
Top disease conditions for chiauranib
Top clinical trial sponsors for chiauranib
US Patents for chiauranib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| chiauranib | ⤷ Start Trial | Non-solvated crystal, preparation method and application thereof | Shenzhen Chipscreen Biosciences Co Ltd | ⤷ Start Trial |
| chiauranib | ⤷ Start Trial | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | Espervita Therapeutics Inc | ⤷ Start Trial |
| chiauranib | ⤷ Start Trial | Tead inhibitors and uses thereof | ImageneBio Inc | ⤷ Start Trial |
| chiauranib | ⤷ Start Trial | CXCR4 inhibitors and uses thereof | X4 Pharmaceuticals Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for chiauranib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| chiauranib | Australia | AU2019328530 | 2038-08-31 | ⤷ Start Trial |
| chiauranib | Brazil | BR112021003467 | 2038-08-31 | ⤷ Start Trial |
| chiauranib | Canada | CA3110735 | 2038-08-31 | ⤷ Start Trial |
| chiauranib | China | CN112839649 | 2038-08-31 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
